Mechanisms of disease: The new β-lactamases

New England Journal of Medicine

Volumn 352, Issue 4, 2005, Pages

  Jacoby, George A ^a,b   Munoz Price, Luisa Silvia ^c  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; BETA LACTAMASE; BETA LACTAMASE AMPC; CARBAPENEM; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CARBENICILLIN; CEFEPIME; CEPHALOSPORIN; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CLAVULANIC ACID; CLOXACILLIN; METICILLIN; MONOBACTAM; OXACILLIN; PENICILLIN G; PIPERACILLIN; PROTEIN EXTENDED SPECTRUM BETA LACTAMASE; TICARCILLIN; UNCLASSIFIED DRUG; UREIDOPENICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM;

AMINO ACID SEQUENCE; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIAL VIRULENCE; DRUG PROTEIN BINDING; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC VARIABILITY; HAEMOPHILUS INFLUENZAE; HAFNIA ALVEI; KLEBSIELLA PNEUMONIAE; MORGANELLA; NEISSERIA GONORRHOEAE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; REVIEW; SEQUENCE ANALYSIS; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; CHEMISTRY; CLASSIFICATION; CONFORMATION; DRUG EFFECT; ENZYMOLOGY; EPIDEMIC; GENETICS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; PHYSIOLOGY; RISK FACTOR;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; DISEASE OUTBREAKS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MOLECULAR CONFORMATION; RISK FACTORS;

EID: 19944434187     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra041359     Document Type: Review

References (118)

1. Joris B, Ghuysen JM, Dive G, et al. The active-site-serine penicillin-recognizing enzymes as members of the Streptomyces R61 DD-peptidase family. Biochem J 1988;250: 313-24.
2. Garau G, García-Sáez I, Bebrone C, et al. Update of the standard numbering scheme for class B β-lactamases. Antimicrob Agents Chemother 2004;48:2347-9.
3. Hall BG, Barlow M. Evolution of the serine β-lactamases: past, present and future. Drug Resist Updat 2004;7:111-23.
4. Medeiros AA. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin Infect Dis 1997;24:Suppl 1:S19-S45.
5. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
6. Bonnet R, Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004;48:1-14.
7. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob Agents Chemother 2002;46:1-11.
8. Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect 2002;8:321-31.
9. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980;289:321-31.
10. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
11. Medeiros AA, Jacoby GA. Beta-lactamase-mediated resistance. In: Queener SF, Webber JA, Queener SW, eds. Beta-lactam antibiotics for clinical use. New York: Marcel Dekker, 1986:49-84.
12. Huang W, Petrosino J, Hirsch M, Shenkin PS, Palzkill T. Amino acid sequence determinants of β-lactamase structure and activity. J Mol Biol 1996;258:688-703.
13. Minasov G, Wang X, Shoichet BK. An ultrahigh resolution structure of TEM-1 β-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc 2002;124:5333-40.
14. Nukaga M, Mayama K, Hujer AM, Bonomo RA, Knox JR. Ultrahigh resolution structure of a class A β-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme. J Mol Biol 2003; 328:289-301.
15. Randegger CC, Keller A, Irla M, Wada A, Hächler H. Contribution of natural amino acid substitutions in SHV extended-spectrum β-lactamases to resistance against various β-lactams. Antimicrob Agents Chemother 2000;44:2759-63.
16. Arlet G, Rouveau M, Philippon A. Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum β-lactamase. FEMS Microbiol Lett 1997;152:163-7.
17. Poirel L, Heritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P. Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV β-lactamase that compromises the efficacy of imipenem. Antimicrob Agents Chemother 2003;47:755-8.
18. Knox JR. Extended-spectrum and inhibitor-resistant TEM-type β-lactamases: mutations, specificity, and three-dimensional structure. Antimicrob Agents Chemother 1995;39:2593-601.
19. Sirot D, Recule C, Chaibi EB, et al. A complex mutant of TEM-1 β-lactamase with mutations encountered in both IRT-4 and extended-spectrum TEM-15, produced by an Escherichia coli clinical isolate. Antimicrob Agents Chemother 1997;41:1322-5.
20. Jacoby G, Bush K. Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant β-lactamases. (Accessed January 3, 2005, at http://www. lahey.org/studies/webt.htm.)
21. Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47:3554-60.
22. Kuzin AP, Nukaga M, Nukaga Y, Hujer AM, Bonomo RA, Knox JR. Structure of the SHV-1 β-lactamase. Biochemistry 1999;38: 5720-7.
23. Yuan M, Aucken H, Hall LMC, Pitt TL, Livermore DM. Epidemiological typing of klebsiellae with extended-spectrum β-lactamases from European intensive care units. J Antimicrob Chemother 1998;41:527-39.
24. Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact. Antimicrob Agents Chemother 2003;47:2385-92.
25. Yong D, Shin JH, Kim S, et al. High prevalence of PER-1 extended-spectrum β-lactamase-producing Acinetobacter spp. in Korea. Antimicrob Agents Chemother 2003;47: 1749-51.
26. Bonnet R, Sampaio JL, Chanal C, et al. A novel class A extended-spectrum β-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother 2000; 44:3061-8.
27. Matsumoto Y, Inoue M. Characterization of SFO-1, a plasmid-mediated inducible class A β-lactamase from Enterobacter cloacae. Antimicrob Agents Chemother 1999;43:307-13.
28. Silva J, Aguilar C, Ayala G, et al. TLA-1: a new plasmid-mediated extended-spectrum β-lactamase from Escherichia coli. Antimicrob Agents Chemother 2000;44:997-1003.
29. Giakkoupi P, Tzouvelekis LS, Tsakris A, Loukova V, Sofianou D, Tzelepi E. IBC-1, a novel integron-associated class A β-lactamase with extended-spectrum properties produced by an Enterobacter cloacae clinical strain. Antimicrob Agents Chemother 2000; 44:2247-53.
30. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999;5:865-79.
31. Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999;43:1362-6.
32. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
33. VIM-7, An evolutionarily distinct metallo-β-lactamase gene in a Pseudomonas aeniginosa isolate from the United States. Antimicrob Agents Chemother 2004;48:329-32.
34. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to impenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48:15-22.
35. Bush K, Singer SB. Biochemical characteristics of extended broad spectrum β-lactamases. Infection 1989;17:429-33.
36. Queenan AM, Foleno B, Gownley C, Wira E, Bush K. Effects of inoculum and β-lactamase activity in AmpC- and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology. J Clin Microbiol 2004;42:269-75.
37. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;41:563-9.
38. Martínez-Martínez L, Pascual A, Hernández- Allés S, et al. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999;43: 1669-73.
39. Hedges RW, Jacob AE. Transposition of ampicillin resistance from RP4 to other replicons. Mol Gen Genet 1974;132:31-40.
40. Rasheed JK, Jay C, Metchock B, et al. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob Agents Chemother 1997;41:647-53.
41. Heffron F, McCarthy BJ, Ohtsubo H, Ohtsubo E. DNA sequence analysis of the transposon Tn3: three genes and three sites involved in transposition of Tn3. Cell 1979; 18:1153-63.
42. CTX-M-9. Antimicrob Agents Chemother 2002;46:2656-61.
43. Quinteira S, Peixe L. Gene cassette organization of a blaVIM-2 carrying integron closely reflects the evolution of antibiotic usage (GenBank accession number AY560837). (Accessed January 3, 2005, at http://www.ncbi.nlm.nih.gov/ entrez/viewer. fcgi?db=nucleotide&val=44894280.)
44. Heritage J, Hawkey PM, Todd N, Lewis IJ. Transposition of the gene encoding a TEM-12 extended-spectrum β-lactamase. Antimicrob Agents Chemother 1992;36:1981-6.
45. Hæggman S, Löfdahl S, Burman LG. An allelic variant of the chromosomal gene for class A β-lactamase K2, specific for Klebsiella pneumoniae, is the ancestor of SHV-1. Antimicrob Agents Chemother 1997;41:2705-9.
46. Babini GS, Livermore DM. Are SHV β-lactamases universal in Klebsiella pneumoniae? Antimicrob Agents Chemother 2000; 44:2230.
47. Chaves J, Ladona MG, Segura C, Coira A, Reig R, Ampurdanés C. SHV-1 β-lactamase is mainly a chromosomally encoded species-specific enzyme in Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:2856-61.
48. Preston KE, Venezia RA, Stellrecht KA. The SHV-5 extended-spectrum β-lactamase gene of pACM1 is located on the remnant of a compound transposon. Plasmid 2004;51: 48-53.
49. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994;170:1622-5.
50. Thomson KS, Smith Moland E. Version 2000: the new β-lactamases of Gram-negative bacteria at the dawn of the new millennium. Microbes Infect 2000;2:1225-35.
51. Joshi SG, Litake GM, Ghole VS, Niphadkar KB. Plasmid-borne extended-spectrum β-lactamase in a clinical isolate of Acinetobacter baumanni. J Med Microbiol 2003;52: 1125-7.
52. Vahaboglu H, Öztürk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-9. [Erratum, Antimicrob Agents Chemother 1998;42:484.]
53. Vahaboglu H, Öztürk R, Aygun G, et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-9. [Erratum, Antimicrob Agents Chemother 1998;42:484.]
54. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32:Suppl 2:S94-S103.
55. Karlowsky JA, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agents Chemother 2003;47:1672-80.
56. Arlet G, Rouveau M, Casin I, Bouvet PJM, Lagrange PH, Philippon A. Molecular epidemiology of Klebsiella pneumoniae strains that produce SHV-4 β-lactamase and which were isolated in 14 French hospitals. J Clin Microbiol 1994;32:2553-8.
57. Quale JM, Landman D, Bradford PA, et al. Molecular epidemiology of a citywide outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002;35:834-41.
58. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517-23.
59. Arpin C, Dubois V, Coulange L, et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47:3506-14.
60. Radice M, Power P, Di Conza J, Gutkind G. Early dissemination of CTX-M-derived enzymes in South America. Antimicrob Agents Chemother 2002;46:602-4.
61. Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimicrob Chemother 2004;54:735-43.
62. Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S. Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from five US States. Antimicrob Agents Chemother 2003;47:2382-3.
63. Black JA, Moland ES, Hossain A, et al. Prevalence of plasmid-mediated AmpC β-lactamases in Klebsiella pneumoniae (KP), Klebsiella oxytoca (KO), Proteus mirabilis (PM), and Salmonella (S) isolates from 42 ICU and 21 non-ICU sites in the United States. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003. abstract.
64. Dunne EF, Fey PD, Kludt P, et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 2000;284: 3151-6.
65. Carattoli A, Tosini F, Giles WP, et al. Characterization of plasmids carrying CMY-2 from expanded-spectrum cephalosporin-resistant Salmonella strains isolated in the United States between 1996 and 1998. Antimicrob Agents Chemother 2002;46:1269-72.
66. Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-β-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41:5407-13.
67. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet 1999;354:955.
68. Oguri T, Igari J, Hiramatsu K, et al. β-lactamase-producing activity and antimicrobial susceptibility of major pathogenic bacteria isolated from clinical samples. Jpn J Antibiot 2002;55:Suppl A:1-28. (In Japanese.)
69. Sader HS, Biedenbach DJ, Jones RN. Global patterns of susceptibility for 21 commonly utilized antimicrobial agents tested against 48,440 Enterobaceriaceae in the SENTRY Antimicrobial Surveillance Program (1997-2001). Diagn Microbiol Infect Dis 2003;47:361-4.
70. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin Infect Dis 2000; 31:1119-25.
71. Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000;38: 1290-2.
72. Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinotobacter baumanni producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003;41:3403-6.
73. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004;39:55-60.
74. Vercauteren E, Descheemaeker P, Ieven M, Sanders CC, Goossens H. Comparison of screening methods for detection of extended-spectrum β-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol 1997;35: 2191-7.
75. Tenover FC, Mohammed MJ, Gorton TS, Dembek ZF. Detection and reporting of organisms producing extended-spectrum β-lactamases: survey of laboratories in Connecticut. J Clin Microbiol 1999;37:4065-70.
76. Stevenson KB, Samore M, Barbera J, et al. Detection of antimicrobial resistance by small rural hospital microbiology laboratories: comparison of survey responses with current NCCLS laboratory standards. Diagn Microbiol Infect Dis 2003;47:303-11.
77. Tenover FC, Mohammed MJ, Stelling J, O'Brien T, Williams R, Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing. J Clin Microbiol 2001;39:241-50.
78. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002;136:834-44.
79. Mangeney N, Niel P, Paul G, et al. A 5-year epidemiological study of extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates in a medium- and long-stay neurological unit. J Appl Microbiol 2000; 88:504-11.
80. Bisson G, Fishman NO, Patel JB, Edelstein PH, Lautenbach E. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species: risk factors for colonization and impact of antimicrobial formulary interventions on colonization prevalence. Infect Control Hosp Epidemiol 2002;23:254-60.
81. Lucet JC, Chevret S, Deere D, et al. Outbreak of multiply resistant enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin Infect Dis 1996;22:430-6.
82. De Champs C, Rouby D, Guelon D, et al. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect 1991;18:5-13.
83. Pena C, Pujol M, Ricart A, et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum β-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997;35:9-16.
84. Ho PL, Chan WM, Tsang KW, Wong SS, Young K. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002;34: 567-73.
85. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: a case control and molecular epidemiologic investigation. J Infect Dis 1996; 174:529-36.
86. Menashe G, Borer A, Yagupsky P, et al. Clinical significance and impact on mortality of extended-spectrum β lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001;33: 188-93.
87. Piroth L, Aube H, Doise JM, Vincent-Martin M. Spread of extended-spectrum β-lactamase-producing Klebsiella pneumoniae: are β-lactamase inhibitors of therapeutic value? Clin Infect Dis 1998;27:76-80.
88. D'Agata E, Venkataraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum β3-lactamase in a tertiary care hospital. J Infect 1998;36:279-85.
89. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998;42:53-8.
90. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004;140:26-32.
91. Du B, Long Y, Liu H, et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002;28:1718-23.
92. Kim YK, Pai H, Lee HJ, et al. Blood-stream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002;46:1481-91.
93. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum β-lactamase Klebsiella pneumoniae: a case-control study in a district teaching hospital in Taiwan. J Hosp Infect 2003;53:39-45.
94. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001;32:1162-71.
95. Hirakata Y, Yamaguchi T, Nakano M, et al. Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa. Clin Infect Dis 2003;37:26-32.
96. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother 1997;41:1830-1.
97. Jett BD, Ritchie DJ, Reichley R, Bailey TC, Sahm DF. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob Agents Chemother 1995;39: 1187-90.
98. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001;45:3548-54.
99. Jacoby GA, Carreras I. Activities of β-lactam antibiotics against Escherichia coli strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1990;34:858-62.
100. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000;30:473-8.
101. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
102. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21:583-92.
103. Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002;34:135-46.
104. Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47: 3442-7.
105. Burgess DS, Hall RG II, Lewis JS II, Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23:1232-7.
106. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004;39:31-7.
107. Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum β-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004;38:243-51.
108. Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001;39:2206-12.
109. Pangon B, Bizet C, Bure A, et al. In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 β-lactamase. J Infect Dis 1989;159:1005-6.
110. Martínez-Martínez L, Hernández-Allés S, Albertí S, Tomás JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1996;40:342-8.
111. Pai H, Kang CI, Byeon JH, et al. Epidemiology and clinical features of blood-stream infections caused by AmpC-type-β-lactamase-producting Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48: 3720-8.
112. Rice LB, Willey SH, Papanicolaou GA, et al. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990;34:2193-9.
113. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119: 353-8.
114. Lucet JC, Decre D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum β-lactamase-producing Enterobacteriaceae in a university hospital. Clin Infect Dis 1999;29:1411-8.
115. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996;23:118-24.
116. Mebis J, Goossens H, Bruyneel P, et al. Decreasing antibiotic resistance of Enterobacteriaceae by introducing a new antibiotic combination therapy for neutropenic fever patients. Leukemia 1998;12:1627-9.
117. Ahmad M, Urban C, Mariano N, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999; 29:352-5.
118. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344: 1329-32.